Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
RET

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

RET

Chemical Structure Cat. No. Product Name CAS No.
cis-Pralsetinib Chemical Structure
BCP31224 cis-Pralsetinib 2097132-93-7
cis-Pralsetinib is a highly potent and selective inhibitor of rearranged during transfection (RET), with IC50 values ranging from 0.3 to 0.4 nM for WT RET and four enzyme variants (V804L, V804M, M918T, CCDC6-RET), and with broad, robust and anti-tumor activity against multiple RET-driven solid tumor types.
LOXO-292 Chemical Structure
BCP30970 LOXO-292 2222755-14-6
LOXO-292 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC50s of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
Pralsetinib Chemical Structure
BCP29411 Pralsetinib 2097132-94-8
Pralsetinib (BLU-667) is a highly potent and selective RET inhibitor with an IC50 of 0.4 nM for wild type RET kinase.
RET Kinase inhibitor 1  Chemical Structure
BCP23560 RET Kinase inhibitor 1  1627856-64-7
GSK3179106 is a potent, selective, first-in-class and gut-restricted RET kinase inhibitor with IC50 of 0.4 and 11 nM in the biochemical assay and cellular assay respectively, 273-fold selectivity over KDR.
AD80 Chemical Structure
BCP25106 AD80 1384071-99-1
AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
AST-487 Chemical Structure
BCP21589 AST-487 630124-46-8
AST 487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM.
TG101209 Chemical Structure
BCP02514 TG101209 936091-14-4
TG101209 is a potent and small molecule JAK2-selective kinase inhibitor with IC50 of 6, 25, 17 and 169 nM for JAK2, FLT3, RET and JAK3, respectively.
Selpercatinib Chemical Structure
BCP29047 Selpercatinib 2152628-33-4
Selpercatinib is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 163, has an IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively. Antineoplastic activity.
BBT594 Chemical Structure
BCP24855 BBT594 882405-89-2
BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.
YN968D1 Hydrochloride Chemical Structure
BCP16050 YN968D1 Hydrochloride 1218779-89-5
Apatinib is a selective VEGFR2 inhibitor with IC50 of 1 nM. Apatinib also potently suppresses the activities of Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. Apatinib has no significant effects on EGFR, Her-2 or FGFR1 in concentrations up to 10 μM.
12下一页共 14 条记录 1 / 2 页 
0086-13720134139